Wall Street analyst estimates for Opus Genetics, Inc. (IRD): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation).
Valuation Ratios
| Price / Book | -40.38 |
| EV / EBITDA | -3.16 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | $589000 | $39.9M | $19.0M | $11.0M | $14.2M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | $589000 | $39.9M | $19.0M | $11.0M | $14.2M |
| Research & Development | $2.4M | $6.6M | $15.2M | $14.4M | $17.7M | $26.9M | $30.8M |
| Selling, General & Admin | $1.8M | $2.8M | $8.1M | $7.3M | $12.0M | $18.2M | $22.0M |
| Operating Expenses | $4.2M | $20.0M | $23.3M | $21.6M | $29.6M | $73.1M | $52.8M |
| Operating Income | -$4.2M | -$20.0M | -$22.7M | $18.2M | -$10.6M | -$62.1M | -$38.6M |
| EBITDA | -$4.8M | -$17.8M | -$56.7M | $18.2M | -$10.0M | -$57.5M | -$48.1M |
| Interest Expense | $1.4M | $6.8M | $2000 | $9000 | $1.3M | 0 | $1.5M |
| Pre-tax Income | -$6.2M | -$24.6M | -$56.7M | $18.2M | -$10.0M | -$57.5M | -$49.6M |
| Income Tax | 0 | 0 | 0 | $315000 | $12000 | 0 | 0 |
| Net Income | -$6.2M | -$24.6M | -$56.7M | $17.9M | -$10.0M | -$57.5M | -$49.6M |
| EPS | $-0.87 | $-5.28 | $-3.82 | $0.90 | $-0.46 | $-2.15 | $-0.80 |
| EPS (Diluted) | $-0.87 | $-5.28 | $-3.82 | $0.87 | $-0.46 | $-2.15 | $-0.80 |
| Shares Outstanding (Diluted) | $7.1M | $4.7M | $14.9M | $20.6M | $21.6M | $26.7M | $622.2M |
Price
| Price | $5.41 |
| Market Cap | $447M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABOS · AGEN · ALEC · CGTX · HURA · INO · MCRB
Explore sector: Healthcare · Biotechnology
More sections of IRD: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks